Allele Biotechnology and SCM Lifescience Sign a Joint Research and Development Agreement to Develop iPSC-based Diabetes Treatment

SAN DIEGO–(BUSINESS WIRE)–lt;a href="" target="_blank"gt;$Celllt;/agt; lt;a href="" target="_blank"gt;#Allele_Biotechlt;/agt;–San Diego-based iPSC specialist company Allele Biotech forms an agreement with South Korea’s SCM Lifescience on using beta cells to treat diabetes.

Click to view original post